ClinicalTrials.gg
CompletedNCT04251182Updated Jul 19, 2024

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

A Phase 2 interventional study of 15mg T3D-959 and 30 mg T3D-959 in Alzheimer Disease, sponsored by T3D Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-07-19.

Sponsored by T3D Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
356th of 1,609
250 · median 73
Started
2021
with 144 others
Phase 2
360 of 1,940
50 open now
Registered
1,161st of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 356th largest by enrollment of the 1,609 interventional ones that give a count, is one of 145 that started in 2021, is one of 360 in phase 2, and was the 1,161st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer's Disease.

Read the detailed description

Study Design \& Methods: Phase 2 multi-center, randomized, double blind, placebo-controlled study of T3D959 15 mg, 30 mg, 45 mg, or matching placebo administered orally once daily for 24 weeks. There will be equal allocation of subject numbers across the four groups. Stratified randomization will be conducted on the basis of ApoE4 genotype so that subjects are randomized into one of the four dose groups within each stratum of ApoE4 status: ApoE4-positive (at least one E4 allele) vs ApoE4-negative (no E4 alleles).

Following informed consent, subjects will enter the screening phase of the study.

Once eligibility is confirmed and before the start of the first dose of study drug, subjects will be randomized on a 1:1:1:1 basis to placebo or T3D959 treatment (15mg, 30mg, 45mg) for the 24-week treatment period. Investigators, subjects, and caregivers will be blinded to the treatment assignment.

Study schedule visits: screening, baseline, weeks 4, 8, 16, 24 and 28 (F/U visit)

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • mild-to-moderate Alzheimer Disease
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a reliable caregiver, an identified adult who, in the opinion of the investigator has sufficient contact to knowledgeably report on the subject's daily cognition, function, behavior, safety, compliance and adherence. Same caregiver(s) must assist the subject throughout the duration of the trial.
  • Have a clinical diagnosis of mild-to-moderate AD (Stage 4 or 5) according to the NIA-AA (National Institute of Aging - Alzheimer's Association) criteria at screening
  • Meet criteria for mild-to-moderate cognitive impairment with (MMSE) score of 14 through 26 at the screening visit.
  • Neuroimaging evidence consistent with the diagnosis of AD
  • Modified Hachinski \</= 4 at screening
  • Clinical Dementia Rating is 0.5 to 2.0 at screening and Clinical Dementia Rating - Sum of Boxes is ≥ 3 at screening
  • Visual and auditory acuity adequate for neuropsychological testing
  • No evidence of hepatic impairment or renal insufficiency

Exclusion criteria

Exclusion Criteria:

  • Have a current diagnosis of a significant psychiatric illness per the V (DSM-V)
  • With untreated clinical depression (GDS >/= 6 at screening and baseline)
  • Have a current diagnosis of a neurological disease other than AD
  • With glycosylated () >/= 7.7 at screening
  • With a diagnosis of unstable diabetes
  • With thyroid disease at screening TSH >5
  • Have any of the following values at the screening visit:

    • and/or AST value that is twice the
    • Total value that exceeds 2 mg/dL
    • Creatinine level >1.5 mg/dL in men or > 1.4 mg/dL in women
    • Positive urinalysis (other than trace result) unless a cause other than renal impairment
    • (GFR) values \<54 mL/min/1.73 m2
    • Gamma-glutamyl transpeptidase (GGT) value that is twice the upper limit of normal
    • Is positive for or anti- virus antibodies at the screening
  • Have a history of moderate or severe congestive heart failure, class III or IV
  • Have experienced a previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within the past 12 months prior to the baseline
  • Have blood pressure reading at screening that is greater than 160/100 mmHg
  • Have a clinically significant unstable illness
  • Have a history of infection
  • Have a history of alcohol, drug abuse or dependence
  • Have a history of cancer within 5 years of the screening
  • Have any surgical or medical condition which may significantly alter the absorption of any drug substance
  • Females who are pregnant, nursing or of and not practicing effective
  • Is required to take excluded medications as specified protocol
  • Have a known or suspected intolerance or to the study drug, closely related compounds
  • Resides in hospital or moderate to high dependency continuous care facility
  • Are non-ambulatory, or wheelchair-bound
  • Have evidence of clinically relevant pathology that in the investigator's opinion could interfere with the study results or put the subject's safety at risk
  • History of swallowing difficulties
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo, matching T3D-959 active capsules, is pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects randomized to placebo will ingest three size 0 placebo capsules once per day in the morning.

    Drug: Placebos

  • Experimental
    15mg T3D-959

    T3D-959 15 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength contains 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest one size 0, 15mg capsule and two placebo capsules once per day in the morning.

    Drug: 15mg T3D-959

  • Experimental
    30mg T3D-959

    T3D-959 30 mg dose: Subjects will ingest two size 0, 15mg capsules and one placebo capsule once per day in the morning.

    Drug: 30 mg T3D-959

  • Experimental
    45mg T3D-959

    T3D-959 45 mg dose: Subjects will ingest three size 0, 15mg capsules once per day in the morning.

    Drug: 45 mg T3D-959

Interventions

  • Oral administration once daily in the morning

    Also known as: T3D-959

  • Oral administration once daily in the morning

    Also known as: T3D-959

  • Oral administration once daily in the morning

    Also known as: T3D-959

  • DrugPlacebos

    Oral administration once daily in the morning

    Also known as: T3D-959 Placebo

06

What researchers measure

Primary outcomes

  1. Efficacy of T3D-959 on cognition

    Change in cognition as assessed by The Alzheimer's Disease Assessment Scale 11-task cognitive subscale (ADAS-Cog11) from baseline to end of treatment visit, compared to placebo

    Time frame: 28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)

  2. Efficacy of T3D-959 on function

    Change in global function as assessed by Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC) from baseline to end of treatment visit, compared to placebo

    Time frame: 28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)

  3. Safety and tolerability of T3D-959

    Safety will be assessed by 1) AEs, clinical labs, ECG, weight, vital signs 2) Geriatric Depression Scale (GDS) 3)Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: 28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)

Secondary outcomes

  1. Efficacy of T3D-959 on executive function

    Change in executive function as assessed by the Digit Symbol Coding Test (DSCT) from baseline to end of treatment visit, compared to placebo

    Time frame: 28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)

  2. Efficacy of T3D-959 on plasma Aβ 42/40 ratio biomarker level

    Change in Aβ 42/40 ratio plasma biomarker from baseline to end of treatment visit, compared to placebo

    Time frame: 28 weeks (Subjects are on active treatment for 24 weeks followed by a 4-week follow-up)

07

Study locations

1 site
  • T3D Therapeutics
    Durham, North Carolina 27709, United States
08

References and documents

Individual participant data

Plan to share: No — A Clinical Study Report (CSR) will be generated within 9 months after database lock. Aggregate study data will be made available in this report.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jan 2023, 22 months.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 22 months is below that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2020
First posted
Jan 31, 2020
StartActual
Mar 1, 2021
Primary completionActual
Jan 20, 2023
CompletionActual
Feb 17, 2023
Last update
Jul 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04251182
Lead sponsor
T3D Therapeutics, Inc.
Collaborators
National Institute on Aging (NIA), Clinilabs, Inc., Alzheimer's Association
Responsible party
Sponsor
First posted
Jan 31, 2020
Start date
Mar 1, 2021
Primary completion
Jan 20, 2023
Completion
Feb 17, 2023
Last update
Jul 19, 2024

Study contacts

Blake Swearingen, MS
study director · T3D Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: T3D-959

Start the discussion